Effect of dexamethasone on the efficacy of daptomycin in the therapy of experimental pneumococcal meningitis

International Journal of Antimicrobial Agents

Volumn 46, Issue 1, 2015, Pages 28-32

  Vivas, M ^a   Force, E ^a   Tubau, F ^b   El Haj, C ^a   Ariza, J ^a   Cabellos, C ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

CNS infection; Lipopeptide; Steroids; Streptococcus pneumoniae

Indexed keywords

DAPTOMYCIN; DEXAMETHASONE; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; FEMALE; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; ANIMAL; BACTERIAL LOAD; CEREBROSPINAL FLUID; CHEMISTRY; DRUG COMBINATION; MENINGITIS, PNEUMOCOCCAL; MICROBIAL SENSITIVITY TEST; RABBIT; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; CEREBROSPINAL FLUID; DAPTOMYCIN; DEXAMETHASONE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; MENINGITIS, PNEUMOCOCCAL; MICROBIAL SENSITIVITY TESTS; RABBITS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 84935007467     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.01.014     Document Type: Article

References (19)

1. Brouwer MC, McIntyre P, Prasad K., van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2013; 6:CD004405.
2. Arditi M, Mason Jr EO, Bradley JS, Tan TQ, Barson WJ, Schutze G.E., et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics and outcome related to penicillin susceptibility and dexameth-asone use. Pediatrics 1998; 102:1087-97.
3. Bernardo WM, Aires FT, Sá FP. Effectiveness of the association of dexameth-asone with antibiotic therapy in pediatric patients with bacterial meningitis. Rev Assoc Med Bras 2012; 58:319-22.
4. McIntyre PB, Berkey CS, King S.M., Schaad UB, Kilpi T, Kanra GY, et al. Dexa-methasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 1997; 278:925-31.
5. De Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549-56.
6. Thomas R, Le Tulzo Y, Bouget J, Camus C., Michelet C, Le Corre P, et al. Trial of dexamethasone treatment for severe bacterial meningitis in adults. Adult Meningitis Steroid Group. Intensive Care Med 1999; 25:475-80.
7. Viladrich PF, Gudiol F, Linares J., Pallarés R, Sabaté I, Rufí G, et al. Evaluation of vancomycin fortherapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991; 35:2467-72.
8. Ricard JD, Wolff M, Lacherade J.C., Mourvillier B., Hidri N, Barnaud G, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis 2007; 44:250-5.
9. Syrogiannopoulos GA, Olsen KD, Reisch J.S., McCracken Jr GH. Dexamethasone in the treatment of experimental Haemophilus influenzae type b meningitis. J Infect Dis 1987; 155:213-9
10. Erratum in: J Infect Dis 1987; 155:1359].
11. Cabellos C, Martínez-Lacasa J, Tubau F, Fernández A, Viladrich PF, Linares J, et al. Evaluation of combined ceftriaxone and dexamethasone therapy in experimental cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother 2000; 45:315-20.
12. Martínez-Lacasa J., Cabellos C, Martos A, Fernández A, Tubau F, Viladrich PF, et al. Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis. J Antimicrob Chemother 2002; 49:507-13.
13. París MM, Hickey SM, Uscher M.I., Shelton S., Olsen KD, McCracken Jr GH. Effect of dexamethasone on therapy of experimental penicillin-and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1994; 38:1320-4.
14. Vivas M, Force E, Garrigós C, Tubau F., Platteel AC, Ariza J, et al. Experimental study of the efficacy of daptomycinforthe treatment of cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother 2014; 69:3020-6.
15. Dacey RG, Sande MA. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother 1974; 6:437-41.
16. Ribes S, Doménech A, Cabellos C., Tubau F, Linares J, Viladrich P.F., et al. Experimental meningitis due to a high-level cephalosporin-resistant strain of Streptococcus pneumoniae serotype 23F. Enferm Infecc Microbiol Clin 2003; 21:329-33 [in Spanish].
17. Chapin-Robertson K, Edberg SC. Measurements of antibiotics in human body fluids: techniques and significance. In: Lorian V, editor. Antibiotics in laboratory medicine. New York, NY: Williams and Wilkins; 1991. p. 295-366.
18. Mook-Kanamori BB, Rouse MS, Kang C.I., van de Beek D, Steckelberg JM, Patel R. Daptomycin in experimental murine pneumococcal meningitis. BMC Infect Dis 2009; 9:50.
19. Egermann U, Stanga Z, Ramin A., Acosta F, Stucki A, Gerber P., et al. Combination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone. Antimicrob Agents Chemother 2009; 53:3030-3.